Drug Interaction Report

Buprenorphine and Carbamazepine: Interaction Details

AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Buprenorphine

Belbuca Brixadi Buprenex BuTrans Simbadol Sublocade Zorbium
+

Carbamazepine

Carbatrol Epitol Equetro Tegretol
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Updated Jul 2, 2026
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 633 documented Buprenorphine interactions, 601 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
At a glance Effects may be weaker Effects may be stronger
The Bottom Line
Carbamazepine can make buprenorphine work less well (risking withdrawal), while together they add risk of heavy sedation, slowed breathing, and serotonin syndrome. Keep taking both as prescribed and let your care team adjust the dose and monitor you.

Here's what's going on. Carbamazepine speeds up the liver enzymes that break down buprenorphine. That means your body clears the buprenorphine faster, so it may not work as well and you could feel opioid withdrawal (things like sweating, chills, aches, or feeling anxious).

At the same time, both drugs can add up in ways that affect your body. Together they may increase the chance of very deep sleepiness, slowed breathing, low blood pressure, or fainting. There's also a small added risk of serotonin syndrome (agitation, fast heartbeat, shivering, muscle twitching). The good news is your care team can manage this by adjusting your dose and watching you closely. Keep taking both as prescribed and tell them how you feel.

Mechanism: Carbamazepine is a potent CYP3A4 inducer; buprenorphine is a CYP3A4 substrate (not a prodrug). Induction lowers buprenorphine exposure (reduced AUC/Cmax), risking reduced analgesia/efficacy and opioid withdrawal. Additionally, additive CNS depression and additive serotonergic effects apply.

  • Direction: Reduced buprenorphine effect; plus additive respiratory depression, sedation, hypotension, syncope, and serotonin syndrome risk.
  • Evidence: Probable. Severity: Major. Onset: Unspecified.
  • Management: If starting carbamazepine, titrate buprenorphine upward to stable effect and monitor for withdrawal; on carbamazepine discontinuation, consider buprenorphine dose reduction. Use a formulation allowing precise titration if needed. Monitor for sedation/respiratory depression and serotonin syndrome; discontinue buprenorphine if serotonin syndrome suspected.
Onset
unspecified
Evidence
probable
Severity
Major

What happens

Reduced buprenorphine exposure, reduced efficacy of buprenorphine, an increased risk of serotonin syndrome and an increased risk of respiratory depression, profound sedation, hypotension and syncope

Interaction Deep Dive

Caution is warranted when carBAMazepine is given together with buprenorphine (a CNS depressant), because the combination can heighten the likelihood of respiratory depression, profound sedation, hypotension, and syncope2. This concurrent use may additionally lower buprenorphine exposure and precipitate opioid withdrawal symptoms. When a patient receiving buprenorphine requires carBAMazepine (a serotonergic CYP3A4 inducer), it is advisable to raise the buprenorphine dose until stable drug effects are reached, while watching for withdrawal. Conversely, if carBAMazepine is stopped in a patient taking buprenorphine, a reduction of the buprenorphine dose should be considered3. For patients being switched from a transmucosal buprenorphine plus carBAMazepine regimen, monitoring is needed to confirm that the buprenorphine exposure delivered by subQ buprenorphine is sufficient. In patients already receiving subQ buprenorphine who then need carBAMazepine, watch for withdrawal. Should the buprenorphine dose prove inadequate and carBAMazepine cannot be lowered or stopped, adjust the buprenorphine dose. If dose adjustment is not feasible, switch to a buprenorphine formulation that allows more precise dose titration. Watch for serotonin syndrome during the start of therapy and during dose adjustments, and discontinue buprenorphine if it is suspected1.

Why it happens (mechanism)

Induction of CYP3A4-mediated metabolism of buprenorphine; additive serotonergic effects; additive CNS depression

How to manage this interaction

Keep taking both medicines as prescribed unless your prescriber tells you otherwise. This combination can be managed with the right dose and monitoring.

  • Your buprenorphine dose may need to be adjusted and individualized by your care team, and they may monitor you more closely, especially when carbamazepine is started or stopped.
  • Watch for withdrawal (aches, chills, anxiety, sweating) and tell your team, since it may mean your buprenorphine level dropped.
  • Also report deep drowsiness, slow or shallow breathing, dizziness, or fainting right away.
  • Report agitation, shivering, fast heartbeat, or muscle twitching, which can signal serotonin syndrome.

Management is individual — confirm any change with your pharmacist or prescriber.

Literature reports

1 report — tap to read

a) Studies have not examined how a concurrently administered CYP3A4 inducer affects buprenorphine exposure in individuals receiving subQ buprenorphine; nevertheless, these interactions have been demonstrated in trials that used transmucosal buprenorphine. Buprenorphine's effects may vary according to the route by which it is given 1.

Common questions

Can I take Buprenorphine and Carbamazepine together?

Carbamazepine can make buprenorphine work less well (risking withdrawal), while together they add risk of heavy sedation, slowed breathing, and serotonin syndrome. Keep taking both as prescribed and let your care team adjust the dose and monitor you. Always confirm with your pharmacist or prescriber before making any change.

How serious is the Buprenorphine and Carbamazepine interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How is the Buprenorphine and Carbamazepine interaction managed?

Keep taking both medicines as prescribed unless your prescriber tells you otherwise. This combination can be managed with the right dose and monitoring. Your buprenorphine dose may need to be adjusted and individualized by your care team, and they may monitor you more closely, especially when carbamazepine is started or stopped. Watch for withdrawal (aches, chills, anxiety, sweating) and tell your… Management is individual — always follow your own care team's guidance.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

From our Q&A

Real reader questions about these medications, each personally answered by our pharmacist:

Questions for your pharmacist

  • Does my dose of Buprenorphine or Carbamazepine need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (3)

  1. Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
  2. Product Information: CARBATROL(R) oral extended-release capsules, carbamazepine oral extended-release capsules. Takeda Pharmaceuticals America Inc (per FDA), Lexington, MA, 2023. DailyMed
  3. Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Was this write-up helpful?
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.